Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen Phase 2 for Foveal Thickening in Wet AMD
NCT00087763Phase 2Completed
- Sponsor
- OSI Eyetech
- Start
- Mar 2004
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
01
Overview
A Phase 2 trial of pegaptanib sodium in exudative age-related macular degeneration, sponsored by OSI Eyetech. Started Mar 2004; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00087763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087763.